Dr. Carlson is interested in the future role of biology as a human technology and is a founder of Biodesic, a consulting firm at the juncture of biology and other disciplines such as marketing, engineering, and investment. He is a serial entrepreneur and has worked to develop new biological technologies in both academic and commercial environments, focusing on molecular measurement and microfluidic systems. He has also developed and published a number of novel metrics for quantifying the impact and progress of biological technologies. Carlson is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press. Dr. Carlson earned a doctorate in Physics from Princeton University in 1997. LinkedIn
Dr. Becky Cap, a 20-year veteran of the life sciences industry, was named Chief Operating Officer of GenCure in February 2016. GenCure, a subsidiary of BioBridge Global, is focused on providing and developing regenerative medicine and cellular therapy products by realizing the potential of donated human cells and tissue to save and enhance lives. Cap earned a bachelor’s degree from Harvard University. She began her career at Dana-Farber Cancer Institute where she gained clinical, laboratory and regulatory experience. While pursuing her MBA at Boston University’s Health Care Management Program, she moved to industry and began working for Eidetics, a consulting firm focused on informing biomedical product development, where her focus was largely on oncology product development. She also has owned her own consulting firm and worked with a number of local startups. LinkedIn
George Bickerstaff joined the Board in July 2017. Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology. He has served Novartis Pharma AG as its Chief Financial Officer and held senior financial positions at IMS Health, Dun & Bradstreet and General Electric. He serves on numerous boards and is currently partner and managing director of M.M. Dillon & Co., an investment bank and financial advisory firm. He brings to the Board operational and international business experience that will be an asset to RoosterBio as we advance our products to commercialization and enter collaborative arrangements with other companies. LinkedIn
Margot Connor CEO of RoosterBio Inc. has over 25 years of diversified Life Science industry experience which includes executive level accountability for business operations, corporate development and M&A. Read Full Bio
Daniella Kranjac is Co-Founder and Managing Partner of Dynamk Capital and has been building life sciences businesses, developing and commercializing life sciences products for 20 years. Having co-founded Wave Biotech LLC from her dormitory room, she and a partner drove the start-up, growth and commercialization of a highly disruptive technology. As Vice President of the organization, Daniella established a high growth company with significant brand recognition, and led the group to a successful exit and acquisition by GE Healthcare in 2007.
At GE Healthcare, Daniella held a variety of strategic, M&A and business development roles. One of her most notable achievements is the success in an entrepreneurial group within the broader GE Healthcare, where a focus on integrating the acquired Xcellerex business enabled global commercialization of a several hundred million dollar enterprise solutions business. Her extensive business development, negotiations and deal-making experience with multinational biopharma and governments in developed and emerging markets provides Dynamk with a broad network of colleagues, customers, innovators and key opinion leaders.
Founder and Chief Product Officer of RoosterBio Inc., Dr. Jon A. Rowley, started RoosterBio in 2013 as part of his personal quest of having the biggest impact possible on the commercial translation of technologies that incorporate living cells, including cellular therapies, engineered tissues, and tomorrow’s medical devices. Read Full Bio